CCORF Maintains Atara Biotherapeutics(ATRA.US) With Buy Rating, Raises Target Price to $21
Atara Biotherapeutics Analyst Ratings
Atara Biotherapeutics: Hold Rating Maintained Amid Financial Shortfalls and Regulatory Uncertainties
H.C. Wainwright Maintains Atara Biotherapeutics(ATRA.US) With Hold Rating
Atara Biotherapeutics (ATRA) Gets a Hold From Stifel Nicolaus
Atara Biotherapeutics Analyst Ratings
Mizuho Securities Upgrades Atara Biotherapeutics(ATRA.US) to Buy Rating, Cuts Target Price to $18
CCORF Maintains Atara Biotherapeutics(ATRA.US) With Buy Rating, Maintains Target Price $13
Atara Biotherapeutics Analyst Ratings
CCORF Maintains Atara Biotherapeutics(ATRA.US) With Buy Rating, Maintains Target Price $13
Atara Biotherapeutics Receives Buy Rating Amidst Positive FDA Review and Solid Financial Outlook
Atara Biotherapeutics Analyst Ratings
Goldman Sachs Maintains Sell on Atara Biotherapeutics, Lowers Price Target to $11
Atara Biotherapeutics Hold Rating Based on Promising Preclinical Data and Awaited Clinical Trials
Stifel Nicolaus Sticks to Its Hold Rating for Atara Biotherapeutics (ATRA)
Atara Biotherapeutics Analyst Ratings
Atara Biotherapeutics: A Balanced Hold Amidst FDA Approval Prospects and Valuation Uncertainties
Analysts Have Conflicting Sentiments on These Healthcare Companies: Deciphera Pharmaceuticals (DCPH), Atara Biotherapeutics (ATRA) and Nkarta (NKTX)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cytek Biosciences (CTKB), Elanco Animal Health (ELAN) and Atara Biotherapeutics (ATRA)
Buy Rating Affirmed for Atara Biotherapeutics on Strong Pipeline and Financial Health